Landmarks in prostate cancer screening.

Area of Science:

• Urology
• Oncology
• Preventive Medicine

Background:

• Prostate-specific antigen (PSA) is crucial for prostate cancer diagnosis and follow-up.
• The efficacy of PSA screening in reducing prostate cancer mortality remains a subject of debate.
• Conflicting results from various studies necessitate a comprehensive review of PSA screening benefits.

Purpose of the Study:

• To evaluate the effectiveness of prostate-specific antigen (PSA) screening in reducing prostate cancer mortality.
• To analyze the evidence from major studies, including the European Randomized Study of Screening for Prostate Cancer (ERSPC).
• To address concerns regarding overdiagnosis and overtreatment associated with PSA screening.

Main Methods:

• Review of existing literature and major randomized controlled trials on PSA screening.
• Analysis of data from studies like the Tyrol Screening Study, Swedish trials, PLCO, and ERSPC.
• Examination of prostate cancer mortality rates and metastatic disease reduction in screened versus unscreened populations.

Main Results:

• The European Randomized Study of Screening for Prostate Cancer (ERSPC) demonstrated a 20% reduction in prostate cancer mortality.
• Longer follow-up in ERSPC centers showed a 31% decrease in metastatic disease.
• Some studies, like the Swedish trials and PLCO, reported no significant mortality benefit, though methodological criticisms exist.

Conclusions:

• Overall evidence supports PSA screening for prostate cancer, with significant mortality reduction observed in large-scale studies like ERSPC.
• Potential risks include biopsy complications, overdiagnosis, and overtreatment.
• Active surveillance is recommended to mitigate risks of overtreatment in eligible patients.